Odyssey Therapeutics, Inc. Common Stock (ODTX) stock: key figures, P/E, revenue and dividend

Health Care · Biotechnology · United States · ISIN US67613T1043

Price
19.83 USD
Market cap
953.00 m USD
P/E (2025)
–
P/S (2025)
320.23
Dividend yield
0.00 %
Net margin
-4,994.86 %
Return on equity (ROE)
30.44 %
Return on assets (ROA)
-55.10 %

Odyssey Therapeutics, Inc. Common Stock financials

Fiscal year20242025
Revenue4.47 m USD2.98 m USD
Gross profit–2.98 m USD
Operating income-135.22 m USD-161.16 m USD
EBIT-128.83 m USD-149.56 m USD
Net income-129.32 m USD-148.65 m USD
Diluted EPS – continuing operations-2.74 USD-5.39 USD

Full history since 2022, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Odyssey Therapeutics, Inc. Common Stock

Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis factor receptor 2 selectively on Treg; a TSLP/IL-33 bispecific antagonist; an oral small molecule interleukin-1 receptor"associated kinase 4 scaffolding inhibitor; and a small molecule inhibitor of IRF5. The company was incorporated in 2021 and is headquartered in Boston, Massachusetts.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.